Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUBODH K BHUCHAR

Allopathic & Osteopathic Physicians Family Medicine

NPI
1629082417
CMS profile
210092
Location
SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,319.47

66 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,312.39 65
Education $7.08 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 66 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUBODH K BHUCHAR

NPI 1629082417 · CMS profile ID 210092

Allopathic & Osteopathic Physicians / Family Medicine

SUGAR LAND, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 66 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629082417?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUBODH K BHUCHAR, NPI 1629082417, CMS profile ID 210092. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 66 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629082417?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SUBODH K BHUCHAR, NPI 1629082417, CMS profile ID 210092. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 66 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629082417?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SUBODH K BHUCHAR, NPI 1629082417, CMS profile ID 210092, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 66 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1629082417?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

66 matching records · $1,319.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 66 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 66.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $23.8212/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131409474 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.7212/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118085156 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.2811/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153560365 CMS
Novo Nordisk Inc $25.5411/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097677315 CMS
GlaxoSmithKline, LLC. $13.2210/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116008555 CMS
AstraZeneca Pharmaceuticals LP $15.2610/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110553220 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.4410/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118085152 CMS
Dexcom, Inc. $24.9810/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153338793 CMS
Novo Nordisk Inc $21.8710/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097282026 CMS
AstraZeneca Pharmaceuticals LP $21.2710/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110547802 CMS
Amgen Inc. $27.7610/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115451305 CMS
Renalytix AI, Inc. $22.9310/08/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1116758534 CMS
Cranial Technologies, Inc $15.6310/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1082230452 CMS
Exact Sciences Corporation $14.9710/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114592328 CMS
AstraZeneca Pharmaceuticals LP $19.4209/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110552688 CMS
Amgen Inc. $18.8009/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117507510 CMS
AstraZeneca Pharmaceuticals LP $21.0009/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110543355 CMS
Dexcom, Inc. $22.6709/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153338791 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.2709/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153431179 CMS
Inspire Medical Systems, Inc. $34.6208/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148043320 CMS
Bayer Healthcare Pharmaceuticals Inc. $25.7208/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086219979 CMS
Lilly USA, LLC $28.7608/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135351177 CMS
Novo Nordisk Inc $23.3208/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096901723 CMS
Renalytix AI, Inc. $24.6308/15/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1116758532 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.1908/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118085150 CMS
PFIZER INC. $14.2608/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131843268 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.7907/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118085154 CMS
AstraZeneca Pharmaceuticals LP $17.7107/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110541499 CMS
Bayer Healthcare Pharmaceuticals Inc. $23.3807/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086204935 CMS
AstraZeneca Pharmaceuticals LP $14.6306/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110542725 CMS
Dexcom, Inc. $13.2606/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153338789 CMS
Amgen Inc. $22.2806/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117507508 CMS
Novo Nordisk Inc $19.7806/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096760574 CMS
Novartis Pharmaceuticals Corporation $29.2306/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086767763 CMS
AstraZeneca Pharmaceuticals LP $26.6005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110554586 CMS
AstraZeneca Pharmaceuticals LP $15.0005/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110538021 CMS
Abbott Laboratories $19.9505/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125158304 CMS
Merck Sharp & Dohme LLC $13.8205/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141596086 CMS
PFIZER INC. $21.8905/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131485468 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.9505/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118085158 CMS
Renalytix AI, Inc. $24.7905/07/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1116758530 CMS
AstraZeneca Pharmaceuticals LP $14.0805/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110539847 CMS
ABBVIE INC. $30.5304/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103323938 CMS
Lilly USA, LLC $14.8504/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135418261 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.6604/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086230414 CMS
Dexcom, Inc. $26.1204/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153338787 CMS
Amgen Inc. $18.4804/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115451309 CMS
AstraZeneca Pharmaceuticals LP $20.6404/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110548896 CMS
Renalytix AI, Inc. $18.6203/28/2024 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1116758528 CMS
Merck Sharp & Dohme LLC $15.0903/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141966689 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $687.61 39
PY2020 $1,479.37 97
PY2021 $1,325.84 71
PY2022 $1,349.84 72
PY2023 $1,008.09 60
PY2024 $1,319.47 66
PY2025 $1,138.61 56

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $464,693.66 97
PY2024 Principal investigator $270,025.76 55
PY2023 Principal investigator $54,587.21 12
PY2022 Principal investigator $87,839.75 24
PY2021 Principal investigator $247,965.53 21
PY2020 Principal investigator $26,693.61 27
PY2019 Principal investigator $57,601.69 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,080.00 12/31/2022 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS - HOUSTO
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 889828675
Principal investigator 1 AstraZeneca Pharmaceuticals LP $549.18 12/31/2022 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 914597889
Principal investigator 1 SANOFI US SERVICES INC. $6,250.00 11/07/2022 Non-covered Recipient Entity
Pioneer Research Solutions Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935632483
Principal investigator 1 SANOFI US SERVICES INC. $50.00 10/04/2022 Non-covered Recipient Entity
Pioneer Research Solutions Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935632507
Principal investigator 1 SANOFI US SERVICES INC. $50.00 09/06/2022 Non-covered Recipient Entity
Pioneer Research Solutions Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935632436
Principal investigator 1 SANOFI US SERVICES INC. $50.00 08/29/2022 Non-covered Recipient Entity
Pioneer Research Solutions Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935632423
Principal investigator 1 SANOFI US SERVICES INC. $750.00 08/08/2022 Non-covered Recipient Entity
Pioneer Research Solutions Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935632495
Principal investigator 1 SANOFI US SERVICES INC. $7,455.00 08/02/2022 Non-covered Recipient Entity
Pioneer Research Solutions Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935632451
Principal investigator 1 ABBVIE INC. $75.00 07/28/2022 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C No dispute reported 06/30/2026 889802687
Principal investigator 1 ABBVIE INC. $1,900.00 07/26/2022 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 889802093
Principal investigator 1 SANOFI US SERVICES INC. $50.00 07/11/2022 Non-covered Recipient Entity
Pioneer Research Solutions Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935632461
Principal investigator 1 SANOFI US SERVICES INC. $50.00 07/05/2022 Non-covered Recipient Entity
Pioneer Research Solutions Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935632473
Principal investigator 1 SANOFI US SERVICES INC. $400.00 06/13/2022 Non-covered Recipient Entity
Pioneer Research Solutions Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935632343
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,900.22 06/08/2022 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 914593041
Principal investigator 1 SANOFI US SERVICES INC. $875.00 05/09/2022 Non-covered Recipient Entity
Pioneer Research Solutions Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935632273
Principal investigator 1 SANOFI US SERVICES INC. $1,065.00 05/03/2022 Non-covered Recipient Entity
Pioneer Research Solutions Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935632263
Principal investigator 1 SANOFI US SERVICES INC. $1,135.80 04/11/2022 Non-covered Recipient Entity
Pioneer Research Solutions Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935632285
Principal investigator 1 SANOFI US SERVICES INC. $1,065.00 03/21/2022 Non-covered Recipient Entity
Pioneer Research Solutions Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 935632169
Principal investigator 1 AstraZeneca Pharmaceuticals LP $49,242.25 03/18/2022 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 No dispute reported 06/30/2026 914597461
Principal investigator 1 Allergan, Inc. $1,436.50 03/08/2022 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 864373351
Principal investigator 1 Allergan, Inc. $322.35 03/08/2022 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Clinical Trial (LIN-MD-66: PED Longterm safety study) No dispute reported 06/30/2026 864373665
Principal investigator 1 Allergan, Inc. $1,501.00 03/01/2022 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Clinical Trial (LIN-MD-66: PED Longterm safety study) No dispute reported 06/30/2026 864371727
Principal investigator 1 Allergan, Inc. $617.50 01/12/2022 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) No dispute reported 06/30/2026 864366809
Principal investigator 1 Allergan, Inc. $969.95 01/12/2022 Non-covered Recipient Entity
PIONEER RESEARCH SOLUTIONS INC
Clinical Trial (LIN-MD-66: PED Longterm safety study) No dispute reported 06/30/2026 864366967